Rheumatology
Conference Coverage
EULAR systemic sclerosis recommendations now include immunosuppressants
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
Conference Coverage
URAT1 inhibitor shows ‘substantial’ uric acid reduction in phase 2 gout trial
The investigational drug, AR882, reduced serum uric acid to levels seen in people without hyperuricemia and gout.
Conference Coverage
Encouraging telitacicept results reported in phase 3 for lupus, phase 2 for Sjögren’s
Results of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept,...
Latest News
Scientists discover variants, therapy for disabling pansclerotic morphea
The JAK inhibitor ruxolitinib dramatically improved wound healing and rashes in patients with the very rare disorder.
Feature
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis
Musculoskeletal symptoms identified in some patients treated with dupilumab for atopic dermatitis could help further understanding of how...
Conference Coverage
Two biologics show no difference in axial spondyloarthritis radiographic progression over 2 years
This study represents the first head-to-head trial comparing the effects of two biologics in axial spondyloarthritis, in this case in patients at...
Conference Coverage
Lupus nephritis: Hopes, questions arise for baricitinib
Results from a small, independently funded, double-blind, active-comparator trial suggest that baricitinib could be beneficial in the treatment of...
Conference Coverage
ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDs
The risk for interstitial lung disease in patients with PsA during the first 5 years after starting a biologic or targeted synthetic DMARD was...
Conference Coverage
Multiple successive biologic to biosimilar switches deemed safe and effective
Triple switching from infliximab biologic to biosimilar for IBD found no new safety or efficacy concerns.
Conference Coverage
Severe hydroxychloroquine nonadherence linked to worse SLE outcomes
Severe nonadherence to hydroxychloroquine in patients with lupus is associated with an increased risk of flare, organ damage, and mortality within...
Conference Coverage
AxSpA remission on TNFi seen in half of patients with comorbid IBD
Those who had IBD for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axSpA remission...